Pamela O. Zizzamia, D.O.
Endocrinology, Diabetes & Metabolism Physician · Enfield, CT
Pamela O. Zizzamia, D.O. is an endocrinology, diabetes & metabolism physician with a practice address in Enfield, Connecticut, and NPI 1568809416, issued on Jun 2, 2013. Check the license (Connecticut 55910, as entered in NPPES) on the Connecticut Medical Examining Board; the Medicare figures below come from public CMS files.
- Name
- Pamela O. Zizzamia
- Credential
- D.O.
- Primary taxonomy
- Endocrinology, Diabetes & Metabolism Physician 207RE0101X
- License numbers
- 55910 CT
273961 MA
Self-reported in NPPES; status is on the state search - Practice location
- 146 Hazard Ave Ste 107, Enfield, CT 06082
- Phone
- (860) 386-5167
- Enumerated
- Jun 2, 2013
- Record last updated
- Dec 12, 2023
- Fax
- (860) 962-4005
- Medicare enrollment
- Enrolled (PECOS I20231016000206); accepts Medicare assignment
- Medical or professional school
- Philadelphia College Of Osteopathic Medicine, 2013
- Telehealth
- Offers telehealth (CMS)
- Entity
- Type 1 · individual
8 nearest endocrinology, diabetes & metabolism physician records → All 214 in Connecticut → Look up another NPI →
Verify Pamela O. Zizzamia in five checks
- 1IdentityNPI record in CMS NPPESNPI lookupConfirmed in NPPES
- 2LicenseActive license and public ordersConnecticut Medical Examining Board
Search for license 55910Check the board - 3Other statesLicenses and actions elsewhereDocInfo (FSMB)Not checked
- 4ExclusionsMedicare and Medicaid bansHHS-OIG exclusion listNot checked
- 5CertificationBoard certificationABMS AOA NCCPA AANPNot checked
73% fewer Medicare Part D claims than the average endocrinology, diabetes & metabolism physician in 2024
697 Medicare Part D claims for 174 beneficiaries, against an average of 2,630 among the 8,223 providers of this specialty who prescribed in Part D. Brand-name drugs were 39% of claims.
Most prescribed
- Levothyroxine Sodium103 claims
- Ozempic64 claims
- Atorvastatin Calcium44 claims
- Jardiance37 claims
- Lisinopril36 claims
- Metformin Hcl Er35 claims
Source: CMS Medicare Part D Prescribers by Provider and Drug, 2024 (data.cms.gov). Part D covers prescriptions for Medicare patients only; drugs with fewer than 11 claims are not published.
Industry payments in 2024: $216.74
8 payments; by number, the most common kind was food and beverage; the largest payer was Abbott Laboratories. The 5,661 providers of this specialty with any payment received $5,742.15 on average. Payments are reported by manufacturers, not by the provider, and are not a sign of wrongdoing.
Source: CMS Open Payments, program year 2024 (openpaymentsdata.cms.gov); average among providers of this specialty with at least one payment.
Pamela O. Zizzamia among 214 endocrinology, diabetes & metabolism physician records in Connecticut
Pamela O. Zizzamia, D.O. is one of 214 endocrinology, diabetes & metabolism physician records with a practice address in Connecticut. 83% of them appear in a Medicare file (Part D prescribing, MIPS, Open Payments or Medicare group billing); this one does. Its NPI, issued in 2013, is newer than 74% of them.
- NPI issued2013 · 74% of these records are older, 21% newer
- In a Medicare fileYes · 83% of these records are
- In the CMS Doctors and Clinicians fileYes · 68% of these records are
- Graduated2013 · median 2004 among the 145 with a school on file
- Record last updated2023 · 60% of these records were not updated in five years or more
Source: CMS NPPES, file of Aug 9, 2026, every record with primary taxonomy 207RE0101X and a Connecticut practice address; Medicare files: CMS Part D Prescribers 2024, MIPS 2023, Open Payments 2024, Doctors and Clinicians (data.cms.gov).
Endocrinology, Diabetes & Metabolism Physician providers in Connecticut
There are 214 endocrinology, diabetes & metabolism physician records in Connecticut.
All 214 in Connecticut → Every provider in Enfield → Endocrinology, Diabetes & Metabolism Physician nationwide →
The 8 endocrinology, diabetes & metabolism physician records with the nearest ZIP codes
- Molly Emott, M.D.Enfield, CT 060821164436127
- Gunjan Gupta, MDEnfield, CT 060821689240715
- Latha Dulipsingh, MDSouth Windsor, CT 060741467439349
- Ameena Madan Paramasivan, M.D.,South Windsor, CT 060741609121904
- Pooja Narwal, M.D.South Windsor, CT 060741578841763
- Yasmine Khan, MDVernon, CT 060661972577518
- Michael Lemay, M.D.Vernon, CT 060661962533380
- Diana Wagner, M.D.Vernon, CT 060661790893022
Common questions
What is Pamela O. Zizzamia, D.O.'s NPI number?
Pamela O. Zizzamia, D.O.'s National Provider Identifier (NPI) is 1568809416, issued on Jun 2, 2013. An NPI identifies a provider in billing; it is not a license.
Where is Pamela O. Zizzamia, D.O. located?
The NPPES record lists a practice address at 146 Hazard Ave Ste 107, Enfield, CT, 06082. Phone: (860) 386-5167. Providers update this record themselves, so call before visiting.
How can I verify Pamela O. Zizzamia, D.O.'s license?
NPPES lists Connecticut license number 55910, as entered by the provider. Search the Connecticut Medical Examining Board at https://www.elicense.ct.gov/Lookup/LicenseLookup.aspx. The NPPES record confirms identity only; the state search shows license status, expiration and public orders.
How much does Pamela O. Zizzamia, D.O. prescribe under Medicare Part D?
In 2024, Pamela O. Zizzamia, D.O. had 697 Medicare Part D claims for 174 beneficiaries; the average among endocrinology, diabetes & metabolism physician prescribers was 2,630. Part D covers Medicare prescriptions only.
Source: CMS National Plan and Provider Enumeration System (NPPES), file of Aug 9, 2026 (NPPES files on CMS.gov); NUCC Health Care Provider Taxonomy. Medicare files from data.cms.gov. An NPI identifies who bills; it is not a license.
Figures on PlainDoctor are read from the federal files each page names (CMS NPPES, Medicare Part D, MIPS, Open Payments; the HHS-OIG exclusion list only as counts) and from Census population estimates, with the file date shown beside them. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error. Data current as of Aug 9, 2026.